{"gene":"TRIP4","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2024,"finding":"The C-terminal ASCH domain of human TRIP4 binds both ssDNA and dsDNA in a sequence-independent manner through two adjacent positively charged surface patches on the domain surface: one patch binds the 5'-end of DNA and the other binds the 3'-end. Crystal structures and mutagenesis experiments confirmed the key residues involved in DNA binding.","method":"Crystal structure determination, biochemical binding assays, site-directed mutagenesis","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures with functional mutagenesis and binding assays in a single rigorous study","pmids":["38870938"],"is_preprint":false},{"year":2025,"finding":"The E3 ubiquitin ligase RNF25 binds TRIP4 and catalyzes non-degradative ubiquitination of TRIP4 at lysine 135, disrupting TRIP4–p65 interactions and thereby liberating p65 to activate NF-κB signaling and upregulate anti-apoptotic effectors (cIAP2, Bcl-2) in renal cell carcinoma.","method":"Co-immunoprecipitation, ubiquitination assay, site-directed mutagenesis (K135), protein interaction studies","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal binding and ubiquitination assay with site-specific mutagenesis, single lab","pmids":["40765826"],"is_preprint":false},{"year":2021,"finding":"TRIP4 functions as a transcriptional activator by binding directly to the DDIT4 gene promoter region (−196 to −11), regulating DDIT4 transcription and subsequent mTOR signaling activation in glioma; this regulation is modulated by HIF1α.","method":"ChIP assay, promoter reporter assay, knockdown/overexpression with in vitro and in vivo phenotypic rescue","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and promoter assay with rescue experiments, single lab","pmids":["34648907"],"is_preprint":false},{"year":2017,"finding":"TRIP4 promotes expression of COX-2 and iNOS in melanoma cells through two mechanisms: indirect activation of NF-κB signaling and direct binding (anchoring) at the COX-2 and iNOS promoters in synergy with the co-activator p300.","method":"ChIP assay, co-activator interaction studies, siRNA knockdown, in vitro and in vivo tumor models","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with promoter occupancy and co-activator interaction, single lab","pmids":["28899685"],"is_preprint":false},{"year":2019,"finding":"TRIP4 knockdown in cervical cancer cells inactivates PI3K/AKT and MAPK/ERK signaling and reduces hTERT binding to the hTERT promoter, indicating TRIP4 regulates hTERT transcription; TRIP4 knockdown also downregulates Rad51 and p-H2AX, increasing radiation sensitivity.","method":"siRNA knockdown, Western blot, ChIP assay, xenograft in vivo model","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and signaling assays with in vivo validation, single lab","pmids":["30905820"],"is_preprint":false},{"year":2025,"finding":"TRIP4 binds to the specific promoter region of GATA2 (demonstrated by pulldown and ChIP experiments) and activates GATA2 transcription; GATA2 acts as a key downstream effector of TRIP4 in promoting cervical cancer progression, as GATA2 overexpression rescues growth inhibition caused by TRIP4 knockdown.","method":"Pulldown assay, ChIP assay, knockdown/overexpression rescue experiments","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and pulldown with epistatic rescue, single lab","pmids":["40180167"],"is_preprint":false},{"year":2021,"finding":"TRIP4 is a subunit of the ASC-1 ribonucleoprotein complex involved in transcriptional coactivation and RNA processing; proteomic profiling of patient fibroblasts carrying a loss-of-function TRIP4 variant showed altered RNA processing and impaired exosome activity, linking TRIP4 function to RNA metabolism.","method":"Exome sequencing, proteomic profiling of patient fibroblasts","journal":"European journal of human genetics : EJHG","confidence":"Low","confidence_rationale":"Tier 3 / Weak — proteomics in patient fibroblasts, single study, no direct mechanistic reconstitution","pmids":["34075209"],"is_preprint":false},{"year":2020,"finding":"miR-518-3p directly targets the 3'UTR of TRIP4 mRNA (confirmed by dual-luciferase reporter assay), suppressing TRIP4 expression and thereby reducing MMP-2 and MMP-9 levels and inhibiting colorectal cancer cell proliferation, invasion, and migration.","method":"Dual-luciferase reporter assay, siRNA knockdown, Western blot","journal":"Biochemistry and cell biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, luciferase reporter with knockdown, limited mechanistic depth","pmids":["32298598"],"is_preprint":false}],"current_model":"TRIP4 (ASC-1) is a transcriptional coactivator that contains an N-terminal C2HC5-type zinc-finger domain and a C-terminal ASCH domain that binds DNA in a sequence-independent manner through two positively charged surface patches; it occupies gene promoters (e.g., DDIT4, COX-2, iNOS, hTERT, GATA2) in complex with co-activators such as p300 to activate transcription, while its activity is regulated by the E3 ligase RNF25, which ubiquitinates TRIP4 at K135 to disrupt TRIP4–p65 interactions and release p65 for NF-κB activation."},"narrative":{"mechanistic_narrative":"TRIP4 (ASC-1) is a transcriptional coactivator that occupies target gene promoters and drives oncogenic transcriptional programs across multiple cancers [PMID:34648907, PMID:28899685, PMID:40180167]. Its C-terminal ASCH domain binds both ssDNA and dsDNA in a sequence-independent manner through two adjacent positively charged surface patches that engage the 5'- and 3'-ends of DNA, providing the structural basis for chromatin association [PMID:38870938]. Through direct promoter occupancy TRIP4 activates transcription of DDIT4 to engage mTOR signaling in glioma [PMID:34648907], COX-2 and iNOS in synergy with the co-activator p300 in melanoma [PMID:28899685], hTERT in cervical cancer where it also supports PI3K/AKT and MAPK/ERK signaling and Rad51-dependent radioresistance [PMID:30905820], and GATA2, which acts as a key downstream effector of TRIP4-driven cervical cancer progression [PMID:40180167]. TRIP4 activity is gated by the E3 ligase RNF25, which catalyzes non-degradative ubiquitination at lysine 135 to disrupt TRIP4–p65 interactions, liberating p65 to activate NF-κB signaling and anti-apoptotic effectors cIAP2 and Bcl-2 in renal cell carcinoma [PMID:40765826]. Beyond these promoter-specific and regulatory findings, the broader chromatin and RNA-processing context of TRIP4 within the ASC-1 complex is not characterized in the available corpus.","teleology":[{"year":2017,"claim":"Established that TRIP4 acts as a direct, promoter-anchored transcriptional activator rather than only an indirect signaling modulator, by showing it occupies COX-2 and iNOS promoters in synergy with p300.","evidence":"ChIP, co-activator interaction studies, and siRNA knockdown in melanoma in vitro and in vivo models","pmids":["28899685"],"confidence":"Medium","gaps":["Does not define the DNA sequence or structural determinants of TRIP4 promoter binding","Mechanism of p300 recruitment versus NF-κB-mediated indirect activation not separated"]},{"year":2019,"claim":"Extended TRIP4's promoter-binding role to hTERT regulation and linked it to PI3K/AKT, MAPK/ERK signaling and DNA-damage response, establishing a role in cancer cell radioresistance.","evidence":"siRNA knockdown, Western blot, ChIP, and xenograft model in cervical cancer","pmids":["30905820"],"confidence":"Medium","gaps":["Whether signaling changes are direct or downstream of altered transcription is unresolved","No structural basis for hTERT promoter binding"]},{"year":2021,"claim":"Defined a specific TRIP4 promoter target (DDIT4, −196 to −11) and connected its transcriptional output to mTOR signaling under HIF1α modulation, giving a concrete gene-to-pathway axis.","evidence":"ChIP, promoter reporter assays, and knockdown/overexpression rescue in glioma in vitro and in vivo","pmids":["34648907"],"confidence":"Medium","gaps":["How HIF1α modulates TRIP4 activity mechanistically is not defined","Direct versus cofactor-dependent DDIT4 binding not resolved"]},{"year":2021,"claim":"Placed TRIP4 within the ASC-1 ribonucleoprotein complex and linked a loss-of-function variant to altered RNA processing and exosome activity, broadening its role beyond promoter-bound transcription.","evidence":"Exome sequencing and proteomic profiling of patient fibroblasts","pmids":["34075209"],"confidence":"Low","gaps":["Correlative proteomics in patient cells without direct mechanistic reconstitution","Composition and function of the ASC-1 complex not mapped","Causal link between variant and RNA-processing defect not established"]},{"year":2024,"claim":"Provided the structural mechanism for TRIP4 chromatin engagement, showing the ASCH domain binds DNA sequence-independently via two positively charged patches contacting the DNA ends.","evidence":"Crystal structure determination, biochemical binding assays, and site-directed mutagenesis of human TRIP4","pmids":["38870938"],"confidence":"High","gaps":["Does not explain how sequence-independent binding achieves promoter specificity in cells","Role of the N-terminal zinc-finger domain in DNA or partner binding not addressed"]},{"year":2025,"claim":"Identified GATA2 as a key direct downstream effector of TRIP4, with GATA2 overexpression rescuing the growth defect of TRIP4 knockdown, providing an epistatic mechanism for TRIP4-driven cervical cancer progression.","evidence":"Pulldown, ChIP, and knockdown/overexpression rescue experiments","pmids":["40180167"],"confidence":"Medium","gaps":["Single-lab epistasis without independent validation","Whether GATA2 is the sole effector is unknown"]},{"year":2025,"claim":"Revealed post-translational control of TRIP4 by RNF25, which ubiquitinates K135 non-degradatively to disrupt TRIP4–p65 binding and unleash NF-κB-driven anti-apoptotic signaling, defining a regulatory switch for TRIP4 function.","evidence":"Co-immunoprecipitation, ubiquitination assay, and K135 site-directed mutagenesis in renal cell carcinoma","pmids":["40765826"],"confidence":"Medium","gaps":["Single-lab finding without reciprocal genetic validation in other contexts","How K135 ubiquitination structurally disrupts the p65 interface is not defined","Whether other E3 ligases regulate TRIP4 is unknown"]},{"year":null,"claim":"How TRIP4's sequence-independent DNA binding is targeted to specific promoters, and how its transcriptional coactivator role integrates with its ASC-1 complex RNA-processing function, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No mechanism linking sequence-independent ASCH–DNA binding to promoter specificity","Composition and stoichiometry of the ASC-1 complex not mapped in the corpus","Cellular localization dynamics of TRIP4 not characterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,3,4,5]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,3,5]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,3,5]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,4]}],"complexes":["ASC-1 ribonucleoprotein complex"],"partners":["RNF25","P300","RELA"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15650","full_name":"Activating signal cointegrator 1","aliases":["Thyroid receptor-interacting protein 4","TR-interacting protein 4","TRIP-4"],"length_aa":581,"mass_kda":66.1,"function":"Transcription coactivator which associates with nuclear receptors, transcriptional coactivators including EP300, CREBBP and NCOA1, and basal transcription factors like TBP and TFIIA to facilitate nuclear receptors-mediated transcription (PubMed:10454579, PubMed:25219498). May thereby play an important role in establishing distinct coactivator complexes under different cellular conditions (PubMed:10454579, PubMed:25219498). Plays a role in thyroid hormone receptor and estrogen receptor transactivation (PubMed:10454579, PubMed:25219498). Also involved in androgen receptor transactivation (By similarity). Plays a pivotal role in the transactivation of NF-kappa-B, SRF and AP1 (PubMed:12077347). Acts as a mediator of transrepression between nuclear receptor and either AP1 or NF-kappa-B (PubMed:12077347). May play a role in the development of neuromuscular junction (PubMed:26924529). May play a role in late myogenic differentiation (By similarity). Also functions as part of the RQC trigger (RQT) complex that activates the ribosome quality control (RQC) pathway, a pathway that degrades nascent peptide chains during problematic translation (PubMed:32099016, PubMed:32579943, PubMed:36302773)","subcellular_location":"Nucleus; Cytoplasm, cytosol; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome","url":"https://www.uniprot.org/uniprotkb/Q15650/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TRIP4","classification":"Not Classified","n_dependent_lines":27,"n_total_lines":1208,"dependency_fraction":0.022350993377483443},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"EIF3B","stoichiometry":0.2},{"gene":"EIF3G","stoichiometry":0.2},{"gene":"EIF4A1","stoichiometry":0.2},{"gene":"G3BP2","stoichiometry":0.2},{"gene":"NPM1","stoichiometry":0.2},{"gene":"RACK1","stoichiometry":0.2},{"gene":"RBM8A","stoichiometry":0.2},{"gene":"RIOK3","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TRIP4","total_profiled":1310},"omim":[{"mim_id":"617066","title":"MUSCULAR DYSTROPHY, CONGENITAL, DAVIGNON-CHAUVEAU TYPE; MDCDC","url":"https://www.omim.org/entry/617066"},{"mim_id":"616866","title":"SPINAL MUSCULAR ATROPHY WITH CONGENITAL BONE FRACTURES 1; SMABF1","url":"https://www.omim.org/entry/616866"},{"mim_id":"614217","title":"ACTIVATING SIGNAL COINTEGRATOR 1 COMPLEX, SUBUNIT 3; ASCC3","url":"https://www.omim.org/entry/614217"},{"mim_id":"614216","title":"ACTIVATING SIGNAL COINTEGRATOR 1 COMPLEX, SUBUNIT 2; ASCC2","url":"https://www.omim.org/entry/614216"},{"mim_id":"614215","title":"ACTIVATING SIGNAL COINTEGRATOR 1 COMPLEX, SUBUNIT 1; ASCC1","url":"https://www.omim.org/entry/614215"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear bodies","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TRIP4"},"hgnc":{"alias_symbol":["HsT17391","ZC2HC5","ASC-1"],"prev_symbol":[]},"alphafold":{"accession":"Q15650","domains":[{"cath_id":"-","chopping":"10-77","consensus_level":"high","plddt":82.0932,"start":10,"end":77},{"cath_id":"-","chopping":"167-233","consensus_level":"high","plddt":87.3688,"start":167,"end":233},{"cath_id":"2.30.130.30","chopping":"428-575","consensus_level":"high","plddt":90.9135,"start":428,"end":575}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15650","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15650-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15650-F1-predicted_aligned_error_v6.png","plddt_mean":71.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TRIP4","jax_strain_url":"https://www.jax.org/strain/search?query=TRIP4"},"sequence":{"accession":"Q15650","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15650.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15650/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15650"}},"corpus_meta":[{"pmid":"24495969","id":"PMC_24495969","title":"Follow-up of loci from the International Genomics of Alzheimer's Disease Project identifies TRIP4 as a novel susceptibility gene.","date":"2014","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/24495969","citation_count":75,"is_preprint":false},{"pmid":"30905820","id":"PMC_30905820","title":"TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK, PI3K/AKT, and hTERT signaling.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30905820","citation_count":73,"is_preprint":false},{"pmid":"28899685","id":"PMC_28899685","title":"The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28899685","citation_count":16,"is_preprint":false},{"pmid":"34075209","id":"PMC_34075209","title":"Exome reanalysis and proteomic profiling identified TRIP4 as a novel cause of cerebellar hypoplasia and spinal muscular atrophy (PCH1).","date":"2021","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/34075209","citation_count":14,"is_preprint":false},{"pmid":"32298598","id":"PMC_32298598","title":"MicroRNA-518-3p suppresses cell proliferation, invasiveness, and migration in colorectal cancer via targeting TRIP4.","date":"2020","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/32298598","citation_count":13,"is_preprint":false},{"pmid":"34648907","id":"PMC_34648907","title":"TRIP4 transcriptionally activates DDIT4 and subsequent mTOR signaling to promote glioma progression.","date":"2021","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34648907","citation_count":9,"is_preprint":false},{"pmid":"40765826","id":"PMC_40765826","title":"BAY11-7082 Targets RNF25 to Reverse TRIP4 Ubiquitination-dependent NF-κB Activation and Apoptosis Resistance in Renal Cell Carcinoma.","date":"2025","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40765826","citation_count":6,"is_preprint":false},{"pmid":"37718780","id":"PMC_37718780","title":"LINC00668 promoted non-small lung cancer progression by miR-518c-3p/TRIP4 axis.","date":"2023","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/37718780","citation_count":2,"is_preprint":false},{"pmid":"40180167","id":"PMC_40180167","title":"GATA2 promotes cervical cancer progression under the transcriptional activation of TRIP4.","date":"2025","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/40180167","citation_count":2,"is_preprint":false},{"pmid":"38870938","id":"PMC_38870938","title":"Biochemical and structural characterization of the DNA-binding properties of human TRIP4 ASCH domain reveals insights into its functional role.","date":"2024","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/38870938","citation_count":1,"is_preprint":false},{"pmid":"38143368","id":"PMC_38143368","title":"'A novel TRIP4 Variant Associated with Peripheral Neuropathy: Expanding the Clinical and Genetic Spectrum of ASC1-Related Myopathy'.","date":"2024","source":"Journal of neuromuscular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/38143368","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":7186,"output_tokens":1853,"usd":0.024677,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8751,"output_tokens":2724,"usd":0.055927,"stage2_stop_reason":"end_turn"},"total_usd":0.080604,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2024,\n      \"finding\": \"The C-terminal ASCH domain of human TRIP4 binds both ssDNA and dsDNA in a sequence-independent manner through two adjacent positively charged surface patches on the domain surface: one patch binds the 5'-end of DNA and the other binds the 3'-end. Crystal structures and mutagenesis experiments confirmed the key residues involved in DNA binding.\",\n      \"method\": \"Crystal structure determination, biochemical binding assays, site-directed mutagenesis\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures with functional mutagenesis and binding assays in a single rigorous study\",\n      \"pmids\": [\"38870938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The E3 ubiquitin ligase RNF25 binds TRIP4 and catalyzes non-degradative ubiquitination of TRIP4 at lysine 135, disrupting TRIP4–p65 interactions and thereby liberating p65 to activate NF-κB signaling and upregulate anti-apoptotic effectors (cIAP2, Bcl-2) in renal cell carcinoma.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, site-directed mutagenesis (K135), protein interaction studies\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding and ubiquitination assay with site-specific mutagenesis, single lab\",\n      \"pmids\": [\"40765826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIP4 functions as a transcriptional activator by binding directly to the DDIT4 gene promoter region (−196 to −11), regulating DDIT4 transcription and subsequent mTOR signaling activation in glioma; this regulation is modulated by HIF1α.\",\n      \"method\": \"ChIP assay, promoter reporter assay, knockdown/overexpression with in vitro and in vivo phenotypic rescue\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and promoter assay with rescue experiments, single lab\",\n      \"pmids\": [\"34648907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TRIP4 promotes expression of COX-2 and iNOS in melanoma cells through two mechanisms: indirect activation of NF-κB signaling and direct binding (anchoring) at the COX-2 and iNOS promoters in synergy with the co-activator p300.\",\n      \"method\": \"ChIP assay, co-activator interaction studies, siRNA knockdown, in vitro and in vivo tumor models\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with promoter occupancy and co-activator interaction, single lab\",\n      \"pmids\": [\"28899685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TRIP4 knockdown in cervical cancer cells inactivates PI3K/AKT and MAPK/ERK signaling and reduces hTERT binding to the hTERT promoter, indicating TRIP4 regulates hTERT transcription; TRIP4 knockdown also downregulates Rad51 and p-H2AX, increasing radiation sensitivity.\",\n      \"method\": \"siRNA knockdown, Western blot, ChIP assay, xenograft in vivo model\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and signaling assays with in vivo validation, single lab\",\n      \"pmids\": [\"30905820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TRIP4 binds to the specific promoter region of GATA2 (demonstrated by pulldown and ChIP experiments) and activates GATA2 transcription; GATA2 acts as a key downstream effector of TRIP4 in promoting cervical cancer progression, as GATA2 overexpression rescues growth inhibition caused by TRIP4 knockdown.\",\n      \"method\": \"Pulldown assay, ChIP assay, knockdown/overexpression rescue experiments\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and pulldown with epistatic rescue, single lab\",\n      \"pmids\": [\"40180167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIP4 is a subunit of the ASC-1 ribonucleoprotein complex involved in transcriptional coactivation and RNA processing; proteomic profiling of patient fibroblasts carrying a loss-of-function TRIP4 variant showed altered RNA processing and impaired exosome activity, linking TRIP4 function to RNA metabolism.\",\n      \"method\": \"Exome sequencing, proteomic profiling of patient fibroblasts\",\n      \"journal\": \"European journal of human genetics : EJHG\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — proteomics in patient fibroblasts, single study, no direct mechanistic reconstitution\",\n      \"pmids\": [\"34075209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-518-3p directly targets the 3'UTR of TRIP4 mRNA (confirmed by dual-luciferase reporter assay), suppressing TRIP4 expression and thereby reducing MMP-2 and MMP-9 levels and inhibiting colorectal cancer cell proliferation, invasion, and migration.\",\n      \"method\": \"Dual-luciferase reporter assay, siRNA knockdown, Western blot\",\n      \"journal\": \"Biochemistry and cell biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, luciferase reporter with knockdown, limited mechanistic depth\",\n      \"pmids\": [\"32298598\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TRIP4 (ASC-1) is a transcriptional coactivator that contains an N-terminal C2HC5-type zinc-finger domain and a C-terminal ASCH domain that binds DNA in a sequence-independent manner through two positively charged surface patches; it occupies gene promoters (e.g., DDIT4, COX-2, iNOS, hTERT, GATA2) in complex with co-activators such as p300 to activate transcription, while its activity is regulated by the E3 ligase RNF25, which ubiquitinates TRIP4 at K135 to disrupt TRIP4–p65 interactions and release p65 for NF-κB activation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TRIP4 (ASC-1) is a transcriptional coactivator that occupies target gene promoters and drives oncogenic transcriptional programs across multiple cancers [#2, #3, #5]. Its C-terminal ASCH domain binds both ssDNA and dsDNA in a sequence-independent manner through two adjacent positively charged surface patches that engage the 5'- and 3'-ends of DNA, providing the structural basis for chromatin association [#0]. Through direct promoter occupancy TRIP4 activates transcription of DDIT4 to engage mTOR signaling in glioma [#2], COX-2 and iNOS in synergy with the co-activator p300 in melanoma [#3], hTERT in cervical cancer where it also supports PI3K/AKT and MAPK/ERK signaling and Rad51-dependent radioresistance [#4], and GATA2, which acts as a key downstream effector of TRIP4-driven cervical cancer progression [#5]. TRIP4 activity is gated by the E3 ligase RNF25, which catalyzes non-degradative ubiquitination at lysine 135 to disrupt TRIP4–p65 interactions, liberating p65 to activate NF-κB signaling and anti-apoptotic effectors cIAP2 and Bcl-2 in renal cell carcinoma [#1]. Beyond these promoter-specific and regulatory findings, the broader chromatin and RNA-processing context of TRIP4 within the ASC-1 complex is not characterized in the available corpus.\",\n  \"teleology\": [\n    {\n      \"year\": 2017,\n      \"claim\": \"Established that TRIP4 acts as a direct, promoter-anchored transcriptional activator rather than only an indirect signaling modulator, by showing it occupies COX-2 and iNOS promoters in synergy with p300.\",\n      \"evidence\": \"ChIP, co-activator interaction studies, and siRNA knockdown in melanoma in vitro and in vivo models\",\n      \"pmids\": [\"28899685\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not define the DNA sequence or structural determinants of TRIP4 promoter binding\", \"Mechanism of p300 recruitment versus NF-κB-mediated indirect activation not separated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended TRIP4's promoter-binding role to hTERT regulation and linked it to PI3K/AKT, MAPK/ERK signaling and DNA-damage response, establishing a role in cancer cell radioresistance.\",\n      \"evidence\": \"siRNA knockdown, Western blot, ChIP, and xenograft model in cervical cancer\",\n      \"pmids\": [\"30905820\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether signaling changes are direct or downstream of altered transcription is unresolved\", \"No structural basis for hTERT promoter binding\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a specific TRIP4 promoter target (DDIT4, −196 to −11) and connected its transcriptional output to mTOR signaling under HIF1α modulation, giving a concrete gene-to-pathway axis.\",\n      \"evidence\": \"ChIP, promoter reporter assays, and knockdown/overexpression rescue in glioma in vitro and in vivo\",\n      \"pmids\": [\"34648907\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How HIF1α modulates TRIP4 activity mechanistically is not defined\", \"Direct versus cofactor-dependent DDIT4 binding not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed TRIP4 within the ASC-1 ribonucleoprotein complex and linked a loss-of-function variant to altered RNA processing and exosome activity, broadening its role beyond promoter-bound transcription.\",\n      \"evidence\": \"Exome sequencing and proteomic profiling of patient fibroblasts\",\n      \"pmids\": [\"34075209\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Correlative proteomics in patient cells without direct mechanistic reconstitution\", \"Composition and function of the ASC-1 complex not mapped\", \"Causal link between variant and RNA-processing defect not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided the structural mechanism for TRIP4 chromatin engagement, showing the ASCH domain binds DNA sequence-independently via two positively charged patches contacting the DNA ends.\",\n      \"evidence\": \"Crystal structure determination, biochemical binding assays, and site-directed mutagenesis of human TRIP4\",\n      \"pmids\": [\"38870938\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not explain how sequence-independent binding achieves promoter specificity in cells\", \"Role of the N-terminal zinc-finger domain in DNA or partner binding not addressed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified GATA2 as a key direct downstream effector of TRIP4, with GATA2 overexpression rescuing the growth defect of TRIP4 knockdown, providing an epistatic mechanism for TRIP4-driven cervical cancer progression.\",\n      \"evidence\": \"Pulldown, ChIP, and knockdown/overexpression rescue experiments\",\n      \"pmids\": [\"40180167\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab epistasis without independent validation\", \"Whether GATA2 is the sole effector is unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed post-translational control of TRIP4 by RNF25, which ubiquitinates K135 non-degradatively to disrupt TRIP4–p65 binding and unleash NF-κB-driven anti-apoptotic signaling, defining a regulatory switch for TRIP4 function.\",\n      \"evidence\": \"Co-immunoprecipitation, ubiquitination assay, and K135 site-directed mutagenesis in renal cell carcinoma\",\n      \"pmids\": [\"40765826\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding without reciprocal genetic validation in other contexts\", \"How K135 ubiquitination structurally disrupts the p65 interface is not defined\", \"Whether other E3 ligases regulate TRIP4 is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TRIP4's sequence-independent DNA binding is targeted to specific promoters, and how its transcriptional coactivator role integrates with its ASC-1 complex RNA-processing function, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No mechanism linking sequence-independent ASCH–DNA binding to promoter specificity\", \"Composition and stoichiometry of the ASC-1 complex not mapped in the corpus\", \"Cellular localization dynamics of TRIP4 not characterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 3, 4, 5]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 3, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 3, 5]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 4]}\n    ],\n    \"complexes\": [\"ASC-1 ribonucleoprotein complex\"],\n    \"partners\": [\"RNF25\", \"p300\", \"RELA\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":4,"faith_total":4,"faith_pct":100.0}}